FARMINGTON, Conn.--(BUSINESS WIRE)--Rallybio LLC, a development-stage biotechnology company, today announced that it has broadened its drug development capabilities with the addition of Douglas Sheridan, PhD. Dr. Sheridan, a seasoned R&D leader, has significant drug development experience, including discovery, strategic planning and clinical program management. He will help advance Rallybio’s mission to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders.
“As we plan our growth strategy and build a strong portfolio of drug development candidates, Doug’s extensive experience in rare diseases will help us tremendously,” said Martin Mackay, PhD, co-founder of Rallybio. “Doug is a high-performing innovator and leader who has successfully brought his own biotech discovery through FDA approval. I am confident that his background will further expand our ability to deliver transformative therapeutics to patients in need.”
Dr. Sheridan brings more than 20 years of R&D experience to Rallybio, both academically and professionally. Dr. Sheridan is a co-inventor of five clinical drug candidates, including an orphan drug, Ultomiris, which was approved by the FDA in 2018. Most recently, he served as Executive Director, Global Program Team Leader at Alexion Pharmaceuticals, where he led the cross functional development team responsible for the strategy, budget and all operational activities required to launch two global development programs.
“Rallybio is positioned for significant growth and the team is highly-capable in the rare disease space,” said Dr. Sheridan. “I very much look forward to contributing to the team’s success and passion for transforming the lives of patients with severe and rare disorders.”
Dr. Sheridan has a PhD in Neuroscience from Yale University. He also holds a B.S. in Biochemistry and Molecular Biology from Pennsylvania State University.
Rallybio was established to identify and accelerate the development of transformative breakthrough therapies for patients with severe and rare disorders. The founders of the company – Martin Mackay, PhD, Stephen Uden, MD, and Jeffrey Fryer, CPA – are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. Named by FierceBiotech as one of its “Fierce 15” Biotech Companies of 2018, the company was recognized as being among “the most promising private biotech startups”. Rallybio announced in April 2018 that it had secured $37.0 million in a Series A funding led by 5AM Ventures, Canaan Partners, and New Leaf Venture Partners, with additional public-sector participation from Connecticut Innovations. The Company is based in Farmington, CT, at the University of Connecticut’s Technology Incubation Program. For more information, please visit www.rallybio.com.